SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Geron Corporation

SG&A Efficiency in Biotech: A Comparative Analysis

In the dynamic world of biotechnology, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial for evaluating corporate performance. Over the past decade, Bio-Techne Corporation has demonstrated a remarkable increase in SG&A efficiency, with expenses growing from approximately $61 million in 2014 to nearly $397 million in 2023. This represents a growth of over 550%, reflecting the company's strategic investments in administrative capabilities and market expansion.

Conversely, Geron Corporation, while showing a steady increase, has maintained a more conservative growth trajectory. From 2014 to 2023, their SG&A expenses rose from about $17 million to $69 million, marking a 300% increase. This disparity highlights differing strategic priorities and market positioning between the two firms. Notably, data for 2024 is incomplete, suggesting potential shifts in future trends. This analysis underscores the importance of SG&A management in sustaining competitive advantage in the biotech sector.